AlzChem Group AG

  • WKN: A2YNT3
  • ISIN: DE000A2YNT30
  • Land: Deutschland

Nachricht vom 01.07.2019 | 08:00

AlzChem Group AG: Shares of AlzChem Group AG are now listed under new ISIN and WKN

DGAP-News: AlzChem Group AG / Key word(s): Miscellaneous

01.07.2019 / 08:00
The issuer is solely responsible for the content of this announcement.


Shares of AlzChem Group AG are now listed under new ISIN and WKN


Trostberg, July 1 2019 - At the last Annual General Meeting on May 14, 2019, the shareholders of AlzChem Group AG resolved, among other things, to consolidate the issued shares at a ratio of 10 to 1. With this measure, the number of shares will be adjusted to a ratio commensurate with the size and value of the company and the stock exchange price per share will thereby be increased to a level customary on the capital market. With the entry of the AGM resolutions in the commercial register, the number of shares will now be reduced from 101,763,350 to 10,176,335. In this connection, the AlzChem shares were allocated the new ISIN DE000A2YNT30, the new WKN A2Y NT3 and the new stock exchange code ACT, under which the securities are listed from now on.

Andreas Niedermaier, CEO of AlzChem Group AG: "The desire for this so-called reverse split was brought to us by shareholders in order to express the high value of our company and the name recognition also in a higher share price. The shareholders' vote on this proposal was unanimous. We are therefore all the more pleased that we have now been able to finally implement the measure so quickly and that the shareholders will hold the shares with the new securities identification number in their deposit accounts from now on. Through our pleasing operative development, the high level of transparency in capital market communication and in cooperation with our designated sponsor Baader Bank, we will continue to support the tradability and thus the trading volume."

About AlzChem
The AlzChem Group is a vertically integrated manufacturer of various chemical products based on the NCN chain. These are products with typical nitrogen-carbon-nitrogen bonding that are used in a wide variety of different industries. The company has a leading position in select niche markets. The strategic focus of growth and the main focus of its extensive research and development are on the business segment Specialty Chemicals. The company has around 1,560 employees at four sites in Germany and three other sites abroad.



01.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

Formycon AG

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Kaufen

24. September 2020